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SUMMARY 
 
Drugs that inhibit the epidermal growth factor receptor, such as ZD1839 or C225, are 
being used increasingly in the treatment of solid tumours. This has led to the appearance 
of new secondary effects. We describe the case of a patient who presented with an 
acneiform eruption secondary to the administration of ZD1839. These lesions healed in 
a few days after stopping the drug. 
 
  
REPORT 
 
Novel chemotherapeutic agents may produce cutaneous side effects. Monoclonal 
antibodies to the epidermal growth factor receptor (EGF-R) and EGF-R-specific 
receptor tyrosine kinase inhibitors are in use in clinical trials for the treatment of solid 
tumours. Among available anti-EGF-R antibodies the most advanced in clinical 
development is C225 (Cetuximab). Furthermore there is a large number of inhibitors of 
the EGF-R tyrosine kinase under clinical development. Gefitinib, also known as 
ZD1839 (IressaTM, Astra-Zeneca, Wilmington, DE, USA) is a low-molecular weight 
quinazolin derivative that inhibits the activation of EGF-R tyrosine kinase through 
competitive binding of the ATP-binding domain of the receptor. It has recently been 
approved by the Food and Drug Administration as monotherapy for the treatment of 
patients with locally advanced or metastatic nonsmall-cell lung cancers (NSCLCs) after 
failure of both platinum-based and docetaxel chemotherapies.1
We present the case of a 50-year-old male diagnosed with lung adenocarcinoma in 
1997. He received surgical treatment (lobectomy) and chemotherapy (paclitaxel, 
cisplatin, gemcitabine, irinotecan, vinorelbine, docetaxel, oxaliplatin, at different 
periods), and adjuvant radiotherapy for successive disease recurrences. In December 
2001, the patient started treatment with ZD1839 at 200 mg daily. Seven days after 
starting this treatment, the patient presented with pustules and erythematous papules on 
the face, trunk, back and presternal area. The patient continued with the treatment and 
after 2 months, because his lesions still persisted, he came to our department. Physical 
examination revealed a papulopustular eruption, located on the seborrhoeic areas of the 
face (Fig. 1a) and on the anterior and posterior aspects of the trunk (Fig. 1b), with no 
comedones or cysts. Bacteriology and mycology cultures of these lesions were negative. 
During this period the patient was not receiving any other drugs. A biopsy from an 
active lesion revealed orthokeratotic hyperkeratosis of the stratum corneum, lymphocyte 
exocytosis in the basal layer of the epidermis, with basal layer hydropic degeneration. A 
dense inflammatory infiltrate of lymphocytes and neutrophils was observed in the 
dermal papillae. Furthermore, there was a perifollicular dense aggregate of 
multinucleated giant cells and macrophages (Fig. 2). Direct immunofluorescence was 
negative for immunoglobulins, fibrinogen and complement. The patient was diagnosed 
as having an acneiform eruption secondary to ZD1839 administration. The drug was 
stopped, and the skin lesions resolved over a 2-week period. 
Blocking the EGF-R inhibits keratinocyte proliferation and migration2 and induces 
apoptosis.3 The EGF-R has also been implicated in keratinocyte differentiation.4 Drugs 
that inhibit the EGF-R could also possibly be useful in the treatment of other diseases 
where EFG-R is implicated, such as psoriasis,5 or epithelial skin tumours.6
  
  
In some histologic studies of patients treated with ZD1839 or C225, keratin plugs and 
microorganisms have been found in dilated infundibula.7–10 These changes are probably 
secondary to an aberrant differentiation of suprabasal keratinocytes, caused by EGF-R 
inhibition, which results in an acneiform eruption. Infundibular necrosis together with 
alopecia were observed in EGF-R knockout mice, suggesting a central role for EGF-R 
also in hair follicle biology.11
EGF-R inhibitors are being increasingly used in the treatment of solid tumours. Side 
effects described include acneiform lesions as in our patient,7,8 seborrhoeic dermatitis, 
paronychia12 necrolytic migratory erythema-like lesions13 acute interstitial pneumonia14 
and gastrointestinal symptoms. Busam et al.7 studied a series of 10 patients with 
metastatic renal carcinoma treated with C225 for 1 week: all 10 patients developed a 
follicular rash in an acneiform distribution. This was accompanied by pain and fisuring 
of the distal finger tips. No infectious cause was found in these patients. Two patients 
had oral ulcers of 2–3 mm, with negative cultures for herpes virus. Our patient did not 
have oral or finger tip lesions. Furthermore, Van Doorn et al.8 recently described an 
acneiform eruption in three patients receiving treatment with ZD1839. These patients 
presented with follicular papules and pustules in an acneiform distribution together with 
generalized cutaneous xerosis and scaling and altered hair growth. Bacteriologic and 
mycologic cultures were performed in all three patients, and Propionibacterium acnes 
was found in one patient. In summary, we describe a further case of a florid acneiform 
eruption secondary to ZD1839. Many of the novel anti-inflammatory and 
chemotherapeutic agents target the EGF-R or related signalling pathways. 
Dermatologists need to be aware of these agents and their cutaneous side effects. 
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Figure 1. (a) Papular–pustular lesions on the seborrhoeic areas of the face; (b) Papular–
pustular lesions also present on the patient’s back. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Orthokeratotic hyperkeratosis and lymphocytic exocytosis with hydropic 
degeneration of the basal layer. There is a dense inflammatory infiltrate in the dermal 
papillae and a perifollicular aggregate of multinucleated giant cells and macrophages. 
